Replimune Group Inc

Replimune Group Inc a biotechnology company develops oncolytic immunogene therapies to treat cancer It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer The companys lead product candidate is RP1 a selectively replicating version of herpes simplex virus 1 which is in Phase III clinical trials for a range of solid tumors and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma It is also developing RP2 which is in Phase I clinical trials for an antiCTLA4 antibodylike protein in order to block the inhibition of the immune response otherwise caused by CTLA4 and RP3 that is in Phase I clinical trials to express immuneactivating proteins that stimulate T cells Replimune Group Inc was founded in 2015 and is headquartered in Woburn Massachusetts